172 related articles for article (PubMed ID: 15682382)
21. Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.
Jaramillo CAC; Belli S; Cascais AC; Dudal S; Edelmann MR; Haak M; Brun ME; Otteneder MB; Ullah M; Funk C; Schuler F; Simon S
MAbs; 2017 Jul; 9(5):781-791. PubMed ID: 28440708
[TBL] [Abstract][Full Text] [Related]
22. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
[TBL] [Abstract][Full Text] [Related]
23. Development and applications of AlphaScreen-based FcRn binding assay to characterize monoclonal antibodies.
Wu Q; Lee HY; Wong PY; Jiang G; Gazzano-Santoro H
J Immunol Methods; 2015 May; 420():31-7. PubMed ID: 25837414
[TBL] [Abstract][Full Text] [Related]
24. Target-independent variable region mediated effects on antibody clearance can be FcRn independent.
Kelly RL; Yu Y; Sun T; Caffry I; Lynaugh H; Brown M; Jain T; Xu Y; Wittrup KD
MAbs; 2016 Oct; 8(7):1269-1275. PubMed ID: 27610650
[TBL] [Abstract][Full Text] [Related]
25. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade.
Liu L; Garcia AM; Santoro H; Zhang Y; McDonnell K; Dumont J; Bitonti A
J Immunol; 2007 Apr; 178(8):5390-8. PubMed ID: 17404325
[TBL] [Abstract][Full Text] [Related]
26. A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K
Maas BM; Cao Y
MAbs; 2018; 10(8):1322-1331. PubMed ID: 30130450
[TBL] [Abstract][Full Text] [Related]
27. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
28. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.
Deng R; Loyet KM; Lien S; Iyer S; DeForge LE; Theil FP; Lowman HB; Fielder PJ; Prabhu S
Drug Metab Dispos; 2010 Apr; 38(4):600-5. PubMed ID: 20071453
[TBL] [Abstract][Full Text] [Related]
30. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
[TBL] [Abstract][Full Text] [Related]
31. Targeting the neonatal Fc receptor (FcRn) to treat autoimmune diseases and maternal-fetal immune cytopenias.
Wyckoff SL; Hudson KE
Transfusion; 2021 May; 61(5):1350-1354. PubMed ID: 33650699
[TBL] [Abstract][Full Text] [Related]
32. Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice.
Lobo ED; Soda DM; Balthasar JP
J Pharm Sci; 2003 Aug; 92(8):1665-76. PubMed ID: 12884253
[TBL] [Abstract][Full Text] [Related]
33. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.
Sockolosky JT; Szoka FC
Adv Drug Deliv Rev; 2015 Aug; 91():109-24. PubMed ID: 25703189
[TBL] [Abstract][Full Text] [Related]
34. Blocking Placental Class G Immunoglobulin Transfer Prevents NMDA Receptor Antibody Effects in Newborn Mice.
García-Serra A; Radosevic M; Ríos J; Aguilar E; Maudes E; Landa J; Sabater L; Martinez-Hernandez E; Planagumà J; Dalmau J
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34580181
[TBL] [Abstract][Full Text] [Related]
35. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
[TBL] [Abstract][Full Text] [Related]
36. Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey.
Ng CM; Fielder PJ; Jin J; Deng R
AAPS J; 2016 Jul; 18(4):948-59. PubMed ID: 27075465
[TBL] [Abstract][Full Text] [Related]
37. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease.
Akilesh S; Petkova S; Sproule TJ; Shaffer DJ; Christianson GJ; Roopenian D
J Clin Invest; 2004 May; 113(9):1328-33. PubMed ID: 15124024
[TBL] [Abstract][Full Text] [Related]
38. Reduced elimination of IgG antibodies by engineering the variable region.
Igawa T; Tsunoda H; Tachibana T; Maeda A; Mimoto F; Moriyama C; Nanami M; Sekimori Y; Nabuchi Y; Aso Y; Hattori K
Protein Eng Des Sel; 2010 May; 23(5):385-92. PubMed ID: 20159773
[TBL] [Abstract][Full Text] [Related]
39. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn).
Ferl GZ; Wu AM; DiStefano JJ
Ann Biomed Eng; 2005 Nov; 33(11):1640-52. PubMed ID: 16341929
[TBL] [Abstract][Full Text] [Related]
40. Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer.
Lobo ED; Balthasar JP
J Pharm Sci; 2005 Sep; 94(9):1957-64. PubMed ID: 16052545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
